← All Indaptus Therapeutics, INC filings

Indaptus Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
INDP
Indaptus Therapeutics, INC
10-K: Indaptus Therapeutics Reports 2024 Results and Provides Business Update
Indaptus Therapeutics, a clinical-stage biotechnology company, released its 2024 financial results and provided an update on its ongoing clinical development programs, including the Phase 1 trial of Decoy20 and a planned combination study with BeiGene's tislelizumab.
NASDAQ
INDP
Indaptus Therapeutics, INC
10-K: Indaptus Therapeutics Reports on 2023 Financials and Clinical Trial Progress
Indaptus Therapeutics, a clinical-stage biotech company, released its 2023 annual report, detailing financial results and progress in its Phase 1 clinical trial for Decoy20.